Sanofi Consumer Healthcare India Limited (SANOFICONR)

Healthcare · Pharmaceuticals & Biotechnology · NSE · Updated 21 July 2026

₹4,528.8 ↓ 10.53% (1Y)

🎯 Key Takeaways

Sanofi Consumer Healthcare India Limited is transitioning from a mature, dividend-focused entity toward a growth-oriented phase driven by product relaunches and international expansion, as evidenced by strong export growth and strategic leadership continuity. Management is actively repositioning the business post-dividend declaration, with renewed emphasis on operational execution and capital allocation clarity.
⚠️ 1) Overreliance on export markets, which remain volatile due to geopolitical and regulatory factors, despite recent growth. 2) Margin sustainability i

Market Cap

₹11,212

P/E Ratio

43.5

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About SANOFICONR 📊 Interactive Charts

📖 The Story

Sanofi Consumer Healthcare India Limited is transitioning from a mature, dividend-focused entity toward a growth-oriented phase driven by product relaunches and international expansion, as evidenced by strong export growth and strategic leadership continuity. Management is actively repositioning the business post-dividend declaration, with renewed emphasis on operational execution and capital allocation clarity.

📰 What's Happening

In Q1 2026, the company reported a 33% YoY revenue increase to ₹2,292 MN and 36% YoY net profit growth to ₹678 MN, fueled by domestic sales growth of 15.5% and a 144% export surge following product relaunches. Shareholders approved the audited FY2025 financials and a final dividend of ₹75 per share at the June 26, 2026 AGM, while reappointing Director Stanislas Camart and appointing Price Waterhouse & Co as statutory auditor for a five-year term. The Board also finalized Q1 2026 results on April 28, 2026, signaling operational momentum ahead of strategic disclosures.

Source: Stock Announcements

🔮 Management Outlook & What's Next

While no formal long-term guidance was provided in recent filings, management highlighted during the June 26, 2026 AGM that the company is focused on sustaining growth momentum, particularly in export markets, and emphasized confidence in the strategic direction under current leadership. The reappointment of Stanislas Camart and auditor ratification signal stability in governance, though forward-looking commentary remains limited.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Pharmaceuticals & Biotechnology

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Sun Pharmaceutical Industries Limited	4.51 L Cr	41.3	20.3%	15.1%	0.03
Divi's Laboratories Limited	1.79 L Cr	72.4	22.1%	16.6%	0.00
Torrent Pharmaceuticals Limited	1.49 L Cr	80.1	—	—	—
Cipla Limited	1.16 L Cr	25.4	19.4%	14.6%	0.00
Dr. Reddy's Laboratories Limited	1.12 L Cr	20.0	19.7%	16.6%	0.12
Lupin Limited	1.04 L Cr	36.2	—	—	—
Mankind Pharma Limited	1.03 L Cr	49.2	—	—	—
Zydus Lifesciences Limited	1.02 L Cr	22.5	—	—	—
Aurobindo Pharma Limited	87,806	25.3	—	—	—
Laurus Labs Limited	71,455	356.8	—	—	—

🔗 Peer Stock Analyses

SUNPHARMA DIVISLAB TORNTPHARM CIPLA DRREDDY

⚠️ Risk Factors

1) Overreliance on export markets, which remain volatile due to geopolitical and regulatory factors, despite recent growth. 2) Margin sustainability is uncertain as input costs and competitive pressures could erode profitability gains. 3) Limited product diversification beyond core consumer healthcare segments increases execution risk. 4) Management’s strategic priorities beyond dividend policy remain under-articulated, creating uncertainty around long-term growth drivers.

📋 Recent Filings

🧠 Analyst's Read

The company is showing signs of operational recovery, but investor focus will shift to how management deploys capital beyond dividends — particularly in innovation, international expansion, or M&A. Execution consistency and clarity on growth strategy will be critical to sustaining momentum.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on SANOFICONR

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-21.

📡 Get AI alerts when SANOFICONR files new disclosures

Track SANOFICONR filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track SANOFICONR — Free

Free account · 2 AI queries/day